top of page

Curevo's CEO describes P2 data released this week showing that amezosvatein may have a better profile than Shingrix

George Simeon explains how the 876-participant study showed non-inferiority vs Shingrix and lower rates of solicited local and systemic adverse events.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page